Category: Psychedelics
-
![Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering]()
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
-
![Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?]()
Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?
“Suicide Opportunity” I can’t remember what company it was, maybe MindMed, but one of their early pitch decks had a page titled ‘Suicide Opportunity’. Yesterday I wrote an article outlining how Seelos Therapeutics was targetting suicide with ketamine-based treatments and it reminded me for a moment of that pitch deck. To note, Seelos didn’t word…
-
![Cybin (CYBN.E) new tryptamine patent improves outcome quality]()
Cybin (CYBN.E) new tryptamine patent improves outcome quality
Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…
-
![Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech]()
Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to raise a considerable amount of cash while having its hands in several different buckets, bringing in $23 million CAD on a bought deal back in February. Mind…
-
![Delic (DELC.C) acquisition target completes $3.43 million private placement]()
Delic (DELC.C) acquisition target completes $3.43 million private placement
Delic Holdings (DELC.C) announced that their acquisition target, Complex Biotech Discovery Venture (CBDV), has closed their previously-announced non-brokered private placement. The private placement consists of 11,441,189 CBDV Subscription Receipts sold at $0.30 each. Every subscription receipt will grant its holder one common share of CBDV and one warrant, exercisable at $0.40 for 24 months after…
-
![Bright Minds Biosciences (DRUG.C) is actually really tight]()
Bright Minds Biosciences (DRUG.C) is actually really tight
Serotonin over psychedelics Bright Minds Biosciences (DRUG.C) isn’t banking on recreational psychedelics being relevant any time soon, they aren’t selling mushroom powder, and don’t own any ketamine clinics. Rather, they are developing novel therapeutics to improve the lives of people with severe and life-altering diseases with a focus on 5-HT (serotonin) medicines. The company does…
-
Delic Holdings (DELC.C) asked to justify promo materials but, to be honest, the materials are good
At Equity.Guru, engaged as we are in market awareness programs for public companies, we often see competing entities that are more promotional than journalistic, banging out borderline insanity regarding their client companies and how they’re all the best thing ever. And when we see something egregious, we’re often the first ones to point it out.…
-
![I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms]()
I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms
Last week Cybin (CYBN.NE) announced it was targetting alcoholism with its novel psychedelic compound CYB003. Another EG staffer wrote a piece last Monday outlining the details of the plan, but I’m going full editorial for this one as I have some experience with the topic. Through a series of psychedelic trips in my teen years,…
-
![Core One Labs (COOL.C) Completes Acquisition of Akome Biotech]()
Core One Labs (COOL.C) Completes Acquisition of Akome Biotech
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological illnesses. “Closing on Akome is an important step for the Company, as we have added an outstanding asset and a strong team. The drug formulations being…
